[Story ID: 810]
When it comes to the documented 40 percent effectiveness of PSA testing in preventing death from prostate cancer, neither the American Cancer Society nor the discoverer of the PSA protein, Richard Ablin, are telling the public the complete story.
[Story ID: 786]
Women’s responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month’s Cancer Biology & Therapy.
[Story ID: 793]
Mayo Clinic is forming a new permanent professorship to augment cancer research that will focus on finding new treatments and preventive measures to reduce the incidence of cancer.
[Story ID: 768]
Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.
[Story ID: 707]
The incidence of colorectal cancer (CRC) in China is lower than that in the west countries, but has increased in recent years and become a substantial cancer burden in China, particularly in the more developed areas.
[Story ID: 679]
Responding to continued debate over PSA screening, and today’
[Story ID: 666]
Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.
[Story ID: 671]
A DRUG commonly used to prevent and treat bones losing density and becoming brittle – known as osteoporosis – may also help reduce the risk of breast cancer by one third or more according to new research published in the British Journal of Cancer today (Wednesday).
[Story ID: 650]
CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).
[Story ID: 630]
Anne Feeley, a 55-year-old mother and brain cancer survivor, will cycle across the country this spring to raise awareness and money for brain cancer research and support.